Business Wire

J-HOTATE Association Exhibits at Seafood Expo Global in Spain to appeal premium and fresh Japanese scallops

15.4.2024 14:00:00 EEST | Business Wire | Press release

Share

Japan Scallop Export Promotion Association (“J-HOTATE Association”), which aims to expand the export of Japanese scallops, will be presenting the Japanese scallops to European markets at the Seafood Expo Global, which will be held in Barcelona, Spain, from April 23rd to April 25th, 2024.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240415920416/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Japanese Scallop - A Sustainable Gastronomic Delight (Photo: Business Wire)

Japanese scallops (we say HOTATE [Hoh-Tah-Teh]) are highly accredited for their flavor, size, and quality. Fresh scallops can be enjoyed year-round under environmentally friendly farming/harvesting methods and the advanced technology to maintain freshness—both of which are unique to Japan. Especially in Hokkaido, Aomori, Iwate, and Miyagi where scallops are produced, local ocean currents provide highly rich nutrients, boasting one of the world’s largest landings of scallops.

Scallops are also known as a healthy seafood. They are rich in nutrients such as vitamin B1, which is effective in alleviating fatigue and improving concentration, and taurine, which is known to improve heart and liver function and help to prevent diabetes. Furthermore, scallops are high in protein and low in calories, making them fit to be a superfood.

Japan is unique to other parts of the world in that the proximity of fishing grounds and ports allows for scallops to be processed and distributed immediately after they are caught, and it has become a common custom in Japan for scallops to be eaten raw. Today, scallops are rapidly frozen right after landing, allowing overseas distribution while maintaining quality.

Exports of Japanese scallop products from Japan to other countries reached a record high of 94.5 billion JPY (approx. 128,000 tons in weight) in 2022, surpassing double its value (over 1.6 times in weight) of that of 2020, when markets stalled due to COVID-19.

Export Data of Japanese Scallops (worldwide)

(Units: tons/millions JPY/kg)

2020

2021

2022

Weight

Amount

PPU

Weight

Amount

PPU

Weight

Amount

PPU

Raw

13,990

5,090

364

19,597

8,173

417

16,356

9,512

582

Dried

1,167

7,154

6,128

994

5,967

6,001

454

3,914

8,628

Frozen

63,556

26,216

412

96,392

55,877

580

111,392

81,099

728

Total

78,713

38,460

489

116,983

70,018

599

128,203

94,526

737

Source: J-HOTATE Association

The association has participated in the Seafood Expo in Boston and Singapore and received positive reactions from local firms of North America and Asian countries interested in connecting with Japanese scallop suppliers.

Our goals with the first exhibition in Europe are to increase the export of Japanese scallops and promote the traditional Japanese "eating raw" culture to taste the fullness of scallops' rich nutritional value. The booth will include a business meeting space, introduction of Japanese scallop products and production areas, as well as showing samples of scallops at regular and frozen temperatures, and providing tasting samples of scallops, shipped straight from Japan in Sushi/Sashimi and fried styles.

[Exhibit Information]
Event: Seafood Expo Global (https://www.seafoodexpo.com/global/)
Booth Number: 1F701 (Hall 1)
Date: April 23–April 25, 2024
Venue: FIRA BARCELONA GRAN VIA VENUE

About Japan Scallop Export Promotion Association (“J-HOTATE Association”)

The Japan Scallop Export Promotion Association (J-HOTATE Association) was incorporated in October 2023, with the aim of expanding exports of Japanese scallop products with high quality and healthy flavours through sustainable cultivation. The J-HOTATE Association is currently composed of seventy-four members, including producers (fishery cooperative associations), processors and fisheries-related distributors of Japan and traders. https://j-hotate.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Media Inquiry:
J-HOTATE Association PR Office (Asahi Agency)
j-hotate@asahi-ag.co.jp

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 15:41:00 EET | Press release

Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye